skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Safety and efficacy of azacitidine in myelodysplastic syndromes

Review

(2574) Views  (872) Full article downloads

Authors: Carlos E Vigil, Taida Martin-Santos, Guillermo Garcia-Manero

Published Date September 2010 Volume 2010:4 Pages 221 - 229
DOI: http://dx.doi.org/10.2147/DDDT.S3143

Carlos E Vigil, Taida Martin-Santos, Guillermo Garcia-Manero
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Purpose: The clinical efficacy, different dosages, treatment schedules, and safety of azacitidine are reviewed.
Summary: Azacitidine is the first drug FDA-approved for the treatment of myelodysplastic syndromes that has demonstrated improvements in overall survival and delaying time to progression to acute myelogenous leukemia. The recommended dosage of azacitidine is 75 mg/m2 daily for 7 days, with different treatment schedules validated. It appears to be well tolerated, with the most common adverse effects being myelosuppression. Several other off-label recommendations were also analyzed.
Conclusion: Azacitidine is the first DNA hypomethylating agent approved by FDA for the treatment of myelodysplastic syndromes with demonstrated efficacy.

Keywords: Azacitidine, MDS, hypomethylating agents






Readers of this article also read:

Induction of cytotoxicity, apoptosis and cell cycle arrest by 1-t-butyl carbamoyl, 7-methyl-indole-3-ethyl isothiocyanate (NB7M) in nervous system cancer cells
Drug design with Cdc7 kinase: a potential novel cancer therapy target
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Functional mobility and balance in community-dwelling elderly submitted to multisensory versus strength exercises
Retinal nerve fiber layer thickness in recovered and persistent amblyopia
Chimeric design, synthesis, and biological assays of a new nonpeptide insulin-mimetic vanadium compound to inhibit protein tyrosine phosphatase 1B
A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCG-refractory and BCG-intolerant patients
Targeting nicotine addiction: the possibility of a therapeutic vaccine
Solid self-nanoemulsifying cyclosporin A pellets prepared by fluid-bed coating: preparation, characterization and in vitro redispersibility
Successful mobilization of peripheral blood stem cells in children with cancer using plerixafor (Mozobil™) and granulocyte-colony stimulating factor
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University